Lung Biotechnology PBC

Quick facts

Phase 2 pipeline

• Beraprost Sodium Modified Release · Cardiovascular
  Beraprost sodium is a prostacyclin analog that acts on the IP receptor to dilate blood vessels and inhibit platelet aggregation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Lung Biotechnology PBC portfolio CI brief
• Lung Biotechnology PBC pipeline updates RSS